How to Read a Peptide Trial on the ANZCTR

What is the ANZCTR?

The ANZCTR, short for the Australian New Zealand Clinical Trials Registry, is a database of clinical trials and their results from Australia, New Zealand and other countries, according to the banner printed on its record pages. The ANZCTR’s About us page records that in 2007 the WHO International Clinical Trials Registry Platform (WHO ICTRP) recognised the ANZCTR as a Primary Registry. Each record page also says the study sponsor and investigators, not the registry, hold responsibility for the study’s safety and scientific validity.

Open a record page and you find a plain list of labels: registration number, ethics application status and dates first, then titles, health condition, intervention, recruitment status and recruiting hospitals. It reads less like an advertisement and more like a project file.

Each record page opened for this guide carries a line worth reading twice: “Listing a study does not mean it has been endorsed by the ANZCTR.” The registry publishes the plan. It does not vouch for the study.

What is an ACTRN?

An ACTRN is the unique registration number the ANZCTR gives a trial. The ANZCTR’s About us page says the number is assigned after approval and that it stays usable throughout the trial’s lifecycle, publications included. On the ANZCTR-native record pages opened for this guide, the number sits in a field labelled “Registration number”. The record for ACTRN12625000026426, opened on 1 October 2026, lists 5 December 2024 as its date submitted and 15 January 2025 as its date registered, a gap worth noticing.

Because the number travels with the trial, a paper published years later can point back to the same page. The ANZCTR’s Register a trial page adds that once approved, a trial is published on the publicly accessible ANZCTR website, so the page behind a code in a news story is open to anyone.

Evidence limits

What does this page’s own registry search cover?

A keyword result shows only that a word appears in a record; the intervention field says what a trial tests, so each record has to be opened and read.

The WHO ICTRP landing page was opened on 1 October 2026; this guide draws no findings from that portal.

What does prospective registration mean?

Prospective registration means a trial is registered before it enrols its first participant. On its Register a trial page, the ANZCTR treats a trial as prospectively registered only when registration comes ahead of the first enrolment. ANZCTR-native record pages, as opened on 1 October 2026, show the outcome in a field called “Type of registration”, which reads “Prospectively registered” or “Retrospectively registered”. The imported ClinicalTrials.gov copies opened that day did not carry that field, so that label belongs to the native records.

The label tells you when the trial was registered relative to its first participant, not what it found. On the record for ACTRN12619000986178, opened on 1 October 2026, it reads “Retrospectively registered”, with 28 May 2019 as the date submitted and 11 July 2019 as the date registered.

What separates an ACTRN from an NCT number?

An ACTRN is the identifier the ANZCTR assigns, and an NCT number is the equivalent identifier assigned by the US registry, ClinicalTrials.gov. Register a trial, the ANZCTR’s guidance page, says a trial conducted entirely outside Australia should consider a more appropriate WHO-recognised registry. The prefixes can still meet on an ANZCTR page: on 1 October 2026, an opened ANZCTR record printed NCT02358356 as its registration number, under the note “Trial details imported from ClinicalTrials.gov”. The table below sets the identifiers side by side.

When a trial carries both identifiers, check that titles, sponsors and dates agree; the import note itself points readers to the original entry.

How does a trial record relate to TGA approval?

The ANZCTR and the TGA’s Australian Register of Therapeutic Goods (ARTG) are separate registers with different jobs. The TGA’s ARTG page describes the ARTG as the place to search medicines, medical devices and biologicals that can be supplied within Australia (TGA, retrieved 2 October 2026), while an ANZCTR record sets out a study’s plan. The TGA’s access-pathways page lists Clinical Trial Schemes among the pathways under which certain registered health practitioners may access unapproved therapeutic goods, if all other clinically appropriate treatment options on the ARTG have been considered (TGA, retrieved 2 October 2026).

This guide treats no registry record as a way to obtain anything.

In a safety advisory published on 13 April 2026, the TGA said that marking a peptide product for research use only does not, by that alone, make its supply lawful or allow its import, and leaves advertising and supply obligations in place. That warning covers the research-use-only wording in this page’s author box and catalogue link.

State law is covered in peptides and Western Australian law, and the origin of “research grade” on a label in what research grade actually means.

Where does ethics review fit in?

ANZCTR record pages treat ethics as its own field, “Ethics application status”, which sits beside the registration dates on record pages opened on 1 October 2026. The NHMRC (the National Health and Medical Research Council) publishes the National Statement, its document on ethical conduct in human research, and its page says the 2025 National Statement is effective from 23 June 2026 (NHMRC, retrieved 2 October 2026). The same NHMRC page says the 2023 edition was in effect from 1 January 2024 to 22 June 2026.

The ethics field records the status of an application, not a finding. On the imported records opened on 1 October 2026, that field was blank, which is a prompt to look further, not a verdict.

What does the evidence look like before a trial is registered?

Some of the literature behind peptide names comes from cells and animals, a stage distinct from a registered human study. Lee and colleagues (Cell Metabolism, 2015) reported MOTS-c, a 16-amino-acid peptide encoded in mitochondrial DNA, in cell and mouse experiments. Chang and colleagues (Journal of Applied Physiology, 2011) reported BPC-157 effects on rat tendon explants and tendon cells in culture. Philp and colleagues (Wound Repair and Regeneration, 2003) reported thymosin beta-4 effects on wounds in rats and mice. Each abstract describes cells, rats or mice, and none describes a human trial.

Lee’s abstract says MOTS-c treatment in mice was tested for effects on insulin resistance and diet-induced obesity. A finding in mice stays a finding in mice.

Chang’s abstract describes BPC-157 as a peptide of 15 amino acids and reports faster outgrowth of cultured tendon explants and more migration of tendon fibroblasts derived from rat Achilles tendon. The BPC-157 research guide gathers the studies this site cites on that peptide. Form Laboratories lists BPC-157 reference material in its research catalogue.

Philp’s group reported that thymosin beta-4 accelerated wound repair in diabetic mice and in 26-month-old mice, and that a seven-amino-acid synthetic peptide, LKKTETQ, matched it in aged animals.